Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

V 212

Next Previous
X
Search
Drug Profile

V 212

Alternative Names: Inactivated varicella-zoster vaccine - Merck; V212; Varicella zoster virus vaccine - Merck; VZV vaccine - Merck

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Herpes zoster

Most Recent Events

  • 11 Apr 2017 Merck completes a phase III trial for Herpes zoster (Prevention) in the US, Argentina, Colombia, Ecuador, Puerto Rico, Belgium, Bulgaria, Estonia, India, South Korea, Spain, Germany, Czech Republic, UK, Austria, Slovakia, Lithuania, Greece and Italy (NCT01254630)
  • 24 Feb 2017 Efficacy and adverse events data from a phase III trial in Herpes zoster released by Merck and Co
  • 29 May 2015 No recent reports on development identified - Phase-II for Herpes zoster (Prevention) in Australia, Canada, Denmark and Israel (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top